Product Description

1cP-LSD Art Blotters 150mcg

1cP-LSD Art Blotters 150mcg(1-cyclopropanoyl-LSD) is a synthetic lysergamide and N1-acylated derivative of LSD, often sold as a novel psychoactive substance (NPS) on blotter paper or in pellets. It is commonly referred to as a “research chemical” and functions primarily as a prodrug for LSD. It has no approved medical uses.

Pharmacology and Mechanism of Action

1cP-LSD acts as a prodrug. The cyclopropanoyl group attached to the indole nitrogen (N1 position) reduces its direct affinity for key receptors, particularly the serotonin 5-HT2A receptor responsible for classic psychedelic effects. In vitro, N1-acylated lysergamides like 1cP-LSD show significantly lower binding affinity and agonist activity at 5-HT2A compared to LSD.

Upon ingestion, 1cP-LSD undergoes hydrolysis (deacylation), especially in human serum or via metabolic processes, releasing active LSD. This conversion explains its LSD-like effects in animal models. In mice, 1cP-LSD induces the head-twitch response (HTR)—a behavioral proxy for hallucinogenic activity—with an ED50 of approximately 430 nmol/kg. This potency is comparable to 1P-LSD (ED50 ~350 nmol/kg) but roughly one-third that of LSD (ED50 ~133 nmol/kg).

Once converted to LSD, the effects are mediated primarily through partial agonism at 5-HT2A receptors (with contributions from other serotonin subtypes like 5-HT1A and 5-HT2C, plus minor dopamine and adrenergic activity). This leads to altered cortical processing, increased glutamate release, disruption of brain networks (e.g., default mode network), and the characteristic perceptual, emotional, and cognitive changes of psychedelics.

Pharmacokinetics: Limited direct human data exist. Analogs like 1P-LSD show rapid conversion to LSD, with near-complete bioavailability of the resulting LSD. Onset is typically 30–90 minutes, peak effects around 2–4 hours, and total duration 6–12 hours (user reports for 1cP-LSD often cite 5–10+ hours). The cyclopropyl group may influence metabolic stability or conversion rate compared to simpler acyl chains.

Subjective Effects

User reports describe effects highly similar to LSD, including visual distortions, altered thinking, time dilation, euphoria/anxiety, introspection, and potential ego dissolution. Common doses (e.g., 100–150 mcg on blotters) are considered roughly comparable to moderate LSD doses after conversion, though individual variability in hydrolysis exists.

Safety Profile

Physiological toxicity of LSD itself is considered low at typical doses, with no well-documented direct fatal overdoses despite decades of use. The estimated lethal dose for LSD is extremely high (thousands of times a recreational dose). Acute effects include elevated heart rate, blood pressure, pupil dilation, and possible nausea or muscle tension.

For 1cP-LSD specifically, human clinical safety data are absent. In silico (computational) toxicology predictions raise some concerns:

• Elevated pulmonary toxicity risk (~81%).
• Genotoxicity alerts (up to ~75–90% probability in some models).
• Possible cardiotoxicity (hERG inhibition) and renal signals.
• Acute LD50 predictions in rats around 49–85 mg/kg (oral/inhalation routes flagged).

These are predictive models only and not confirmed in humans or animals. Structural modifications (bulkier cyclopropyl group) may alter lipophilicity, metabolism, or off-target effects compared to other analogs.

Primary risks remain psychological and behavioral:

• Acute anxiety, panic, paranoia, or “bad trips.”
• Potential precipitation of latent mental health issues (e.g., psychosis in vulnerable individuals).
• Hallucinogen Persisting Perception Disorder (HPPD).
• Impaired judgment leading to accidents.

Unknowns: Long-term effects, exact conversion efficiency, purity of street/research products, and interactions (e.g., with SSRIs, stimulants, or other drugs) are poorly characterized. Variability in deacylation could lead to inconsistent LSD exposure.

Legal status (as of 2026): Varies widely. Controlled or banned in many countries (e.g., UK, Germany under NPS laws, Sweden, Australia). Unscheduled or in gray areas in places like the US (may fall under Federal Analogue Act if for human consumption) and Canada. Always check local laws.

Bottom line: 1cP-LSD appears to deliver LSD-like effects primarily via metabolic conversion, with somewhat lower direct potency. While LSD has a history of low physiological toxicity, 1cP-LSD carries uncertainties due to limited research, predicted toxicological signals, and product variability. This information is for educational and scientific purposes only and does not encourage use. Consult peer-reviewed literature and healthcare professionals for any concerns. Psychedelic substances can have powerful psychological impacts and should be approached with caution and full awareness of legal and health risks.

Additional Information